Investigation conclusion: customer's complaint was not replicated with in-house testing of retain lot w61602b.No issues with ckmb or myo recovery were observed.Manufacturing batch records for lot w61602b were reviewed and found that the lot met release specifications.Based on the information available, there is no indication of a product deficiency and no corrective action is required.Although this catalog number (97300eu) is not approved in the united states, this event is being reported as the device is same/similar to catalog number 97300, 510(k) number k080269.
|
The following events occurred in (b)(6): discrepant low sob panel results as compared to cardiac panel results using a whole blood sample.Ckmb: sob panel= 3.2 ng/ml and cardiac panel= 7.5 ng/ml (normal range= 0-4.3 ng/ml) myoglobin: sob panel= 180 ng/ml and cardiac panel= 336 ng/ml (normal range= 0-170 ng/ml).Ekg diagnosis was acute ischemic cardiomyopathy and acute congestive heart failure.The diagnosis of the patient was non-insulin dependent diabetes mellitus with other complications, primary essential hypertension, and congestive heart failure.The treatment for the patient was ambulatory with enalapril, acetil salicylic acid, citorvastatin, insulin, metformin and glybenclamid.The treatment of the patient was based on cardiac panel results and not the questioned sob panel results.The customer later performed the testing with plasma and the reported receiving a closer correlation.
|